Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionFagan Associates, Inc.
Latest Disclosed Ownership26,553 shares
Latest Disclosed Value $ 11,856,977
Fagan Associates, Inc. reports 0.05% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 4, 2026 - Fagan Associates, Inc. filed a 13F-HR form disclosing ownership of 26,553 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $11,856,977 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 30, 2026 disclosing 26,566 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -0.05% during the quarter. The current value of the position is $11,373,712 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-04 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 26,553 -13 -0.05 11,857 -1.55 1.6486
2026-01-30 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 26,566 260 0.99 12,044 16.90 1.6058
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 26,306 111 0.42 10,302 -11.66 1.4225
2025-08-07 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 26,195 -90 -0.34 11,662 -8.48 1.8039
2025-05-06 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 26,285 -233 -0.88 12,743 19.34 2.1256
2025-02-03 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 26,518 93 0.35 10,679 -13.11 1.6965
2024-11-12 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 26,425 -70 -0.26 12,290 -1.04 2.0647
2024-08-09 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 26,495 557 2.15 12,419 14.54 2.1726
2024-05-06 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 25,938 496 1.95 10,842 4.73 2.0314
2024-02-08 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 25,442 355 1.42 10,352 18.67 2.2502
2023-10-31 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 25,087 510 2.08 8,724 0.87 2.1088
2023-08-08 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 24,577 433 1.79 8,649 13.68 2.0987
2023-05-04 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 24,144 -97 -0.40 7,607 8.67 1.8929
2023-01-26 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 24,241 250 1.04 7,000 0.78 1.8666
2022-11-02 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 23,991 270 1.14 6,946 3.92 1.9415
2022-08-03 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 23,721 -2,178 -8.41 6,684 -1.11 1.7856
2022-05-06 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 25,899 2,480 10.59 6,759 31.42 1.3867
2022-02-08 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 23,419 3,012 14.76 5,143 38.92 0.9756
2021-11-09 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 20,407 -1,035 -4.83 3,702 -14.37 0.8045
2021-08-06 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 21,442 3,157 17.27 4,323 10.03 0.9232
2021-05-06 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18,285 14,570 392.19 3,929 347.49 0.9188
2021-02-08 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,715 3,715 878 0.2205
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.